Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms.

Psychopharmacology - 1 Jul 2020

Boloc Daniel, Rodríguez Natalia, Torres Teresa, García-Cerro Susana, Parellada Mara, Saiz-Ruiz Jeronimo, Cuesta Manuel J, Bernardo Miquel, Gassó Patricia, Lafuente Amalia, Mas Sergi, Arnaiz Joan Albert

Abstract excerpt

INTRODUCTION: We explore the transcription factors involved in the molecular mechanism of antipsychotic (AP)-induced acute extrapyramidalsymptoms (EPS) in order to identify new candidate genes for pharmacogenetic studies. METHODS: Protein-protein interaction (PPI) networks previously created from three pharmacogenomic models (in vitro, animal, and peripheral blood inhumans) were used to, by means of several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Basal Ganglia Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computational Biology

Share to Follow-Up Studies

Share to Longitudinal Studies

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Protein Binding

Source

Identifiers

PMID: 32382784
DOI: 10.1007/s00213-020-05526-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms.PMID 32382784Read ↗

Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychoticsSemantic proximity Read ↗

Identification of novel proteins associated with movement-related adverse antipsychotic effects by integrating GWAS data and human brain proteomes.Semantic proximity Read ↗

Pathway and network embedding methods for prioritizing psychiatric drugsSemantic proximity Read ↗

Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.Semantic proximity Read ↗

Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway.Semantic proximity Read ↗

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.Semantic proximity Read ↗

Genomewide association study of movement-related adverse antipsychotic effects.Semantic proximity Read ↗

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.Semantic proximity Read ↗

Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics.Semantic proximity Read ↗

Integrating Genome-wide and Epigenome-wide Associations for Antipsychotic Induced Extrapyramidal Side EffectsSemantic proximity Read ↗

Integrating genome-wide and epigenome-wide associations for antipsychotic induced extrapyramidal side effects.Semantic proximity Read ↗

Psychotropic drug effects on gene transcriptomics relevant to Alzheimer disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.